Technology | August 06, 2013

CIRS announces Stereotactic End-to-End Verification Phantom at AAPM Annual Meeting

Cirus Inc. STEEV QA System Radiosurgery Radiation Therapy Phantom

August 6, 2013 — CIRS will introduce the Stereotactic End-to-End Verification Phantom (STEEV) at the 55th Annual AAPM Meeting and Exhibition on August 4 to 8 in Indianapolis.

CIRS Stereotactic End-to-End Verification Phantom (STEEV™) shown with 12 optional inserts.

STEEV is a QA tool for evaluating stereotactic radiosurgery (SRS) system performance during commissioning and daily systems checks. To facilitate patient QA, STEEV serves as a surrogate patient to assess every step of the treatment process- from immobilization and multi-modality imaging (computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)) to thorough treatment plan verification. STEEV's anthropomorphic, tissue-equivalent design makes it the only phantom to account for the challenging effects of tissue heterogeneity.

SRS is a non-invasive procedure that focuses high doses of radiation to destroy tumor volumes in small areas of the body. The procedure necessitates a high degree of accuracy in target localization and dose delivery, because small errors can result in significant under treatment of portions of the tumor volume or overdose of nearby healthy tissues. By providing challenging system checks, STEEV helps to identify system errors and ultimately leads to better patient outcomes- a key component to CIRS' company values.

The introduction of STEEV compliments CIRS' existing suite of site-specific end-to-end QA phantoms, including the Dynamic Thorax Phantom, Dynamic Pelvis Phantom and SBRT Thorax Phantom.

For more information: www.cirsinc.com 


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Artificial Intelligence

June 27, 2024 — The American College of Radiology (ACR) launched the ACR Recognized Center for Healthcare-AI (ARCH-AI) ...

Time June 27, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
Subscribe Now